Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach

Jung-Hsien Chiang | Devin C. Koestler | Celine Vens | Jian Peng | Vatsal Sharan | Brooke L. Fridley | Jaume Bacardit | Wenwen Min | Jinfeng Xiao | Nazem Atassi | Neta Zach | Merit Cudkowicz | Raquel Norel | Jonathan Gordon | Wojciech Lesinski | Adam Godzik | Kenneth Jung | Chen Yang | Boaz Lerner | Jouhyun Jeon | Gustavo Stolovitzky | Xiaohui Xie | Davide Chicco | Kris Sankaran | Fan Fan | Lester Mackey | Witold Rudnicki | Dorota H. Sendorek | Jeremy Jacobsen | Rama Raghavan | Wing Chung Wong | Samad Jahandideh | Barbara Di Camillo | Shihua Zhang | Joseph Usset | Yoav Bar-Sinai | Christoph Kurz | Thea Norman | Krzysztof Mnich | Lara Mangravite | Aneta Polewko-Klim | Christopher M. Lalansingh | Jeremy R. Jacobsen | Yu-Jia Shiah | Nicola Lazzarini | Shadrielle Melijah G. Espiritu | Wen-Chieh Fang | Catalina Anghel | Yeeleng S. Vang | John Balser | Robin Bliss | Alex G. Karanevich | Orla Hardiman | Janelle Noel-MacDonnell | Maya Bronfeld | Bruce Hoff | Junqiang Dai | Yuelong Guo | Javier Garcia-Garcia | Donna E. Dillenberger | Ehsan Saghapour | Tim Herpelinck | Shanfeng Zhu | Noa Ben-David | Stefan Graw | A. Godzik | B. Lerner | R. Norel | Lester W. Mackey | Vatsal Sharan | Jonathan Gordon | K. Jung | D. Chicco | Jian Peng | B. Di Camillo | B. Fridley | G. Stolovitzky | Shihua Zhang | David Wadden | L. Mangravite | A. Chiò | O. Hardiman | Thea C. Norman | B. Hoff | Jouhyun Jeon | J. Bacardit | M. Cudkowicz | J. Hopkins | R. Alkallas | C. Vens | Kris Sankaran | J. Chiang | Jinfeng Xiao | J. Salomond | P. Février | Javier García-García | Samad Jahandideh | Hsih-te Yang | D. Koestler | J. Noel-MacDonnell | Liuxia Wang | S. M. Espiritu | Shanfeng Zhu | Richard Meier | A. Golinska | Yu-Jia Shiah | Haichen Zhang | N. Zach | N. Atassi | Melanie L Leitner | Guang Li | Junqiang Dai | Rama Raghavan | A. Polewko-Klim | W. Lesiński | Krzysztof Mnich | W. Rudnicki | M. Bronfeld | Robert Kueffner | Melanie L. Leitner | Thomas Larrieu | Adriano Chio | Catalina Anghel | V. Balagurusamy | Xihui Lin | T. Larrieu | Hsih-Te Yang | Joseph S. Durgin | Venkat Balagurusamy | Donna Dillenberger | Xihui Lin | Liuxia Wang | Ehsan Saghapour | C. Kurz | Richard Meier | Yuelong Guo | M. Kozák | Jean-Bernard Salomond | Philippe Fevrier | Joshua Knight | Guang Li | Rached Catalina Jeanne Jaume Barbara John Yoav Noa Eyal R Alkallas Anghel Avril Bacardit Balser Bals | Rached Alkallas | Jeanne Avril | Barbara Balser | Eyal Ben-Zion | Jialu Cai | Anatoly Chernyshev | Bhavna Ahuja Nicole Corriveau | Yash Deshpande | Eve Desplats | Agnieszka Golińska | Julia Hopkins | Barbara Huang | Wenkai Ji | Alex Karanevich | Michael Kozak | Christopher Lalansingh | Xiaotao Liang | Jarrett Lowe | Violette Nahmias | Adrienne O’Donnell | Susan Paadre | Ji Park | Dorota Sendorek | Jean-Karl Sirois | Dinithi N. Sumanaweera | Dave Wadden | David Wang | Zhiqing Xu | Xiang Yu | Haichen Zhang | Li Zhang | Huan-Jui Chang | Joseph Usset | A. Chernyshev | Y. S. Vang | B. Balser | Jean-Karl Sirois | J. Lowe | Stefan Graw | Wenkai Ji | N. Lazzarini | R. Kueffner | Joshua Knight | Wen-Chieh Fang | Tim Herpelinck | A. O’Donnell | Xiaotao Liang | John Balser | Dinithi Sumanaweera | Susan Paadre | Huan J. Chang | Wenwen Min | Noa Ben-David | J. Avril | Yoav Bar-Sinai | Eyal Ben-Zion | R. Bliss | Jialu Cai | Yash Deshpande | Eve Desplats | Fan Fan | Barbara Huang | Violette Nahmias | J. Park | David Wang | Xiaohui Xie | Zhiqing Xu | Xiang Yu | Li Zhang | Chen-Wei Yang | Catalina V. Anghel | S. M. G. Espiritu | Jarrett Lowe | Ji Park | T. Herpelinck | C. Lalansingh | D. Sumanaweera | S. Jahandideh | Kenneth Jung | Barbara Balser | Nicola Lazzarini | Dinithi N. Sumanaweera

[1]  R. Tibshirani,et al.  Lasso and Elastic-Net Regularized Generalized Linear Models [R package glmnet version 4.0-2] , 2020 .

[2]  Hemant Ishwaran,et al.  Random Survival Forests , 2008, Wiley StatsRef: Statistics Reference Online.

[3]  L. H. van den Berg,et al.  Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[4]  Project MinE Sequencing Consortium.  Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis , 2018 .

[5]  J. Shefner,et al.  Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis , 2018, JAMA neurology.

[6]  Stephen A. Goutman,et al.  Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression , 2017, JAMA neurology.

[7]  Ivo D. Dinov,et al.  Complete hazard ranking to analyze right-censored data: An ALS survival study , 2017, PLoS Comput. Biol..

[8]  Y. Itoyama,et al.  Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial , 2017, The Lancet Neurology.

[9]  C. Brayne,et al.  Benefits, pitfalls, and future design of population-based registers in neurodegenerative disease , 2017, Neurology.

[10]  S. Rigatti.  Random Forest. , 2017, Journal of insurance medicine.

[11]  G. Logroscino.  Classifying change and heterogeneity in amyotrophic lateral sclerosis , 2016, The Lancet Neurology.

[12]  M. de Carvalho,et al.  Sialorrhoea and reversals in ALS functional rating scale , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  Neta Zach,et al.  Predicting disease progression in amyotrophic lateral sclerosis , 2016, Annals of clinical and translational neurology.

[14]  William T. Hu,et al.  Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population , 2016, Neurology.

[15]  Sandra D'Alfonso,et al.  Association of a Locus in the CAMTA1 Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis. , 2016, JAMA neurology.

[16]  Li Liu,et al.  A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis , 2016, PLoS Comput. Biol..

[17]  Stephen A. Goutman,et al.  Increased ratio of circulating neutrophils to monocytes in amyotrophic lateral sclerosis , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[18]  Paul Wicks,et al.  How common are ALS plateaus and reversals? , 2016, Neurology.

[19]  Adriano Chiò,et al.  Association of a Locus in the CAMTA 1 GeneWith Survival in PatientsWith Sporadic Amyotrophic Lateral Sclerosis , 2016 .

[20]  Orla Hardiman,et al.  Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm , 2015, Journal of Neurology.

[21]  Neta Zach,et al.  Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS? , 2015, Neurotherapeutics.

[22]  Leon Glass,et al.  Dynamical disease: Challenges for nonlinear dynamics and medicine. , 2015, Chaos.

[23]  D. Stekel,et al.  A machine learning heuristic to identify biologically relevant and minimal biomarker panels from omics data , 2015, BMC Genomics.

[24]  Erhan Bilal,et al.  Understanding the limits of animal models as predictors of human biology: lessons learned from the sbv IMPROVER Species Translation Challenge , 2014, Bioinform..

[25]  M. Copetti,et al.  Stratification of ALS patients’ survival: a population-based study , 2016, Journal of Neurology.

[26]  Johann S. Hawe,et al.  Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression , 2014, Nature Biotechnology.

[27]  M. Cudkowicz,et al.  The PRO-ACT database , 2014, Neurology.

[28]  R. Conwit,et al.  Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial , 2014, The Lancet Neurology.

[29]  W. Robberecht,et al.  The phenotypic variability of amyotrophic lateral sclerosis , 2014, Nature Reviews Neurology.

[30]  A. Chiò,et al.  Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. , 2014, JAMA neurology.

[31]  L. H. van den Berg,et al.  A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[32]  R. Küffner,et al.  Physiology of Geobacter metallireducens under excess and limitation of electron donors. Part I. Batch cultivation with excess of carbon sources. , 2014, Systematic and applied microbiology.

[33]  Jun Ma,et al.  On the maximum penalized likelihood approach for proportional hazard models with right censored survival data , 2014, Comput. Stat. Data Anal..

[34]  Rui Huang,et al.  An exploratory study of serum creatinine levels in patients with amyotrophic lateral sclerosis , 2014, Neurological Sciences.

[35]  Edward I. George,et al.  Variable selection for BART: An application to gene regulation , 2013, 1310.4887.

[36]  Aixia Guo,et al.  Gene Selection for Cancer Classification using Support Vector Machines , 2014 .

[37]  A. Chiò,et al.  Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[38]  J. Connor,et al.  Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis. , 2013, JAMA neurology.

[39]  O. Hardiman,et al.  Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial , 2013, The Lancet Neurology.

[40]  D. Morris,et al.  Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing , 2013, Journal of Medical Genetics.

[41]  N. Nishimoto,et al.  Tocilizumab infusion therapy normalizes inflammation in sporadic ALS patients. , 2013, American journal of neurodegenerative disease.

[42]  M. Sabatelli,et al.  Clinical and genetic heterogeneity of amyotrophic lateral sclerosis , 2013, Clinical genetics.

[43]  M. Swash,et al.  Controversies and priorities in amyotrophic lateral sclerosis , 2013, The Lancet Neurology.

[44]  Martin Mozina,et al.  Orange: data mining toolbox in python , 2013, J. Mach. Learn. Res..

[45]  Diogo M. Camacho,et al.  Wisdom of crowds for robust gene network inference , 2012, Nature Methods.

[46]  S. Paganoni,et al.  What does body mass index measure in amyotrophic lateral sclerosis and why should we care? , 2012, Muscle & nerve.

[47]  S. Paganoni,et al.  Uric acid levels predict survival in men with amyotrophic lateral sclerosis , 2012, Journal of Neurology.

[48]  Stef van Buuren,et al.  MICE: Multivariate Imputation by Chained Equations in R , 2011 .

[49]  A. Chiò,et al.  ALS clinical trials , 2011, Neurology.

[50]  R. Norel,et al.  The self-assessment trap: can we all be better than average? , 2011, Molecular systems biology.

[51]  S. Paganoni,et al.  Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis , 2011, Muscle & nerve.

[52]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[53]  R. Conwit,et al.  Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet Neurology.

[54]  Daniel Stahl,et al.  Latent Cluster Analysis of ALS Phenotypes Identifies Prognostically Differing Groups , 2009, PloS one.

[55]  A. L. La Spada,et al.  ALS motor phenotype heterogeneity, focality, and spread , 2009, Neurology.

[56]  A. Pestronk,et al.  Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III , 2009, Annals of neurology.

[57]  C. Coffman,et al.  Factors associated with survival in the National Registry of Veterans with ALS , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[58]  M. Swash,et al.  Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[59]  B. Mohammadi,et al.  ALSFRS-R score and its ratio: A useful predictor for ALS-progression , 2008, Journal of the Neurological Sciences.

[60]  W. Bamlet,et al.  Subcutaneous IGF-1 is not beneficial in 2-year ALS trial , 2008, Neurology.

[61]  J. Frost,et al.  Social Uses of Personal Health Information Within PatientsLikeMe, an Online Patient Community: What Can Happen When Patients Have Access to One Another’s Data , 2008, Journal of medical Internet research.

[62]  I. Heilberg,et al.  Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[63]  J. Hauw,et al.  Causes of death in a post‐mortem series of ALS patients , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[64]  H. Mitsumoto,et al.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial , 2007, The Lancet Neurology.

[65]  Z. Simmons,et al.  Respiratory systems abnormalities and clinical milestones for patients with amyotrophic lateral sclerosis with emphasis upon survival , 2007, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[66]  R. Miller,et al.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). , 2002, The Cochrane database of systematic reviews.

[67]  Andy Liaw,et al.  Classification and Regression by randomForest , 2007 .

[68]  S. Appel,et al.  Amyotrophic lateral sclerosis: early predictors of prolonged survival , 2006, Journal of Neurology.

[69]  S H Appel,et al.  Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[70]  D. Schoenfeld,et al.  Functional outcome measures as clinical trial endpoints in ALS , 2004, Neurology.

[71]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[72]  Adriano Chiò,et al.  Acute migraine treatment with droperidol , 2003, Neurology.

[73]  Miller Rg,et al.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) , 2003 .

[74]  T D Koepsell,et al.  Prognosis in amyotrophic lateral sclerosis , 2003, Neurology.

[75]  R. Miller,et al.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[76]  M. Naumann,et al.  Disease progression in amyotrophic lateral sclerosis: Predictors of survival , 2002, Muscle & nerve.

[77]  J. Friedman.  Greedy function approximation: A gradient boosting machine. , 2001 .

[78]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[79]  Chih-Ping Wei,et al.  Empirical comparison of fast clustering algorithms for large data sets , 2000, Proceedings of the 33rd Annual Hawaii International Conference on System Sciences.

[80]  D. Schoenfeld,et al.  Combining mortality and longitudinal measures in clinical trials. , 1999, Statistics in medicine.

[81]  B. Brooks,et al.  El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis , 1994, Journal of the Neurological Sciences.

[82]  G. Celeux,et al.  A Classification EM algorithm for clustering and two stochastic versions , 1992 .

[83]  J. MacQueen.  Some methods for classification and analysis of multivariate observations , 1967 .

[84]  H. E. Hurst,et al.  Long-Term Storage Capacity of Reservoirs , 1951 .